Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Non Operating Income (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Non Operating Income readings, the most recent being $443000.0 for Q4 2023.

  • On a quarterly basis, Non Operating Income rose 164.2% to $443000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $550000.0, a 118.71% increase, with the full-year FY2025 number at -$1.9 million, up 73.13% from a year prior.
  • Non Operating Income hit $443000.0 in Q4 2023 for Elicio Therapeutics, up from $113000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.2 million in Q2 2021 to a low of -$16.7 million in Q1 2021.
  • Median Non Operating Income over the past 4 years was -$438500.0 (2020), compared with a mean of -$2.7 million.
  • Biggest five-year swings in Non Operating Income: crashed 2744.44% in 2022 and later skyrocketed 164.2% in 2023.
  • Elicio Therapeutics' Non Operating Income stood at -$15.0 million in 2020, then surged by 101.7% to $256000.0 in 2021, then tumbled by 369.53% to -$690000.0 in 2022, then skyrocketed by 164.2% to $443000.0 in 2023.
  • The last three reported values for Non Operating Income were $443000.0 (Q4 2023), $113000.0 (Q3 2023), and $218000.0 (Q2 2023) per Business Quant data.